Loading…

Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction

AbstractIntroductionEndovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective of this study is to determine if the Model for End-Stage Liver Disease (M...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2017-11, Vol.16 (6), p.950-958
Main Authors: Torres-Machorro, Adriana, Guerrero-Hernandez, Manuel, Anaya-Ayala, Javier E, Torre, Aldo, Laparra-Escareno, Hugo, Cuen-Ojeda, Cesar, Garcia-Alva, Ramón, Hinojosa, Carlos A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c417t-7e6504b9b1874656d1e028f6ab1cb3c28fe8e419da80885b8ae7efe53ebc664d3
container_end_page 958
container_issue 6
container_start_page 950
container_title Annals of hepatology
container_volume 16
creator Torres-Machorro, Adriana
Guerrero-Hernandez, Manuel
Anaya-Ayala, Javier E
Torre, Aldo
Laparra-Escareno, Hugo
Cuen-Ojeda, Cesar
Garcia-Alva, Ramón
Hinojosa, Carlos A
description AbstractIntroductionEndovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective of this study is to determine if the Model for End-Stage Liver Disease (MELD) score is a useful method to evaluate the risk of morbidity and mortality during endovascular approaches. Material and methodsPatients that underwent endovascular reconstruction of the PV or spleno-mesenteric confluence were identified retrospectively. Data were collected from November 2011 to August 2016. The MELD score was calculated using international normalized ratio, serum billirubin and creatinine. Patients were grouped into moderate (≤15) and high (> 15) MELD. Associations of the MELD score on the postprocedural morbidity, mortality and vessels patency were assessed by two-sided Fisher's exact test. ResultsSeventeen patients were identified; MELD score distribution was: ≤ 15 in 10 patients (59%) and > 15 in 7 (41%). Even distribution of severe PV thrombosis was treated in both groups, performing predominately jugular access in the high MELD score group (OR 0.10; 95%; CI 0.014-0.89; p = 0.052) in contrast to a percutaneous transhepatic access in the moderate MELD score group. Analysis comparing moderate and high MELD scores was not able to demonstrate differences in mortality, morbidity or patency rates. ConclusionMELD score did not prove to be a useful method to evaluate risk of morbidity and mortality; however a high score should not contraindicate endovascular approaches. In our experience a high technical success, good patency rates and low complication rates were observed.
doi_str_mv 10.5604/01.3001.0010.5287
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a06e85cfa743489eb2ea7c07f7c8bd5d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1665268119304636</els_id><doaj_id>oai_doaj_org_article_a06e85cfa743489eb2ea7c07f7c8bd5d</doaj_id><sourcerecordid>1954387156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-7e6504b9b1874656d1e028f6ab1cb3c28fe8e419da80885b8ae7efe53ebc664d3</originalsourceid><addsrcrecordid>eNo9kc1vFCEYhzlobK3-AV7MHL1sheFzLiZNXesma2qs7cUDAeYdZWWGFZgm-9-X6dYe-MjL8_4gPAi9I_icC8w-YnJOcZ3qqJVWyRfolAjBV61Q5AS9znmHMaOctK_QSdthzjuKT9Gvi8mEQ_a5iUNT_kDzbb393Ny4mKDZjHvjSuOnx4Prubg4wsKtpz7em-zmYFLzPaZiQnMHlfsBLk65pNkVH6c36OVgQoa3T-sZuv2y_nn5dbW9vtpcXmxXjhFZVhIEx8x2lijJBBc9AdyqQRhLnKWubkEBI11vFFaKW2VAwgCcgnVCsJ6eoc0xt49mp_fJjyYddDRePxZi-q1NKt4F0AYLUNwNRjLKVAe2BSMdloN0yvZ8yfpwzNqn-G-GXPTos4MQzARxzpp0nFElCRcVJUfUpZhzguH5aoL14kRjohcnenGiFye15_1T_GxH6J87_gupwKcjAPXD7j0k7YKfvDPhLxwg7-KcqrD6Dp1bjfXNongxTGozE1TQB0CbnW4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954387156</pqid></control><display><type>article</type><title>Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction</title><source>ScienceDirect</source><creator>Torres-Machorro, Adriana ; Guerrero-Hernandez, Manuel ; Anaya-Ayala, Javier E ; Torre, Aldo ; Laparra-Escareno, Hugo ; Cuen-Ojeda, Cesar ; Garcia-Alva, Ramón ; Hinojosa, Carlos A</creator><creatorcontrib>Torres-Machorro, Adriana ; Guerrero-Hernandez, Manuel ; Anaya-Ayala, Javier E ; Torre, Aldo ; Laparra-Escareno, Hugo ; Cuen-Ojeda, Cesar ; Garcia-Alva, Ramón ; Hinojosa, Carlos A</creatorcontrib><description>AbstractIntroductionEndovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective of this study is to determine if the Model for End-Stage Liver Disease (MELD) score is a useful method to evaluate the risk of morbidity and mortality during endovascular approaches. Material and methodsPatients that underwent endovascular reconstruction of the PV or spleno-mesenteric confluence were identified retrospectively. Data were collected from November 2011 to August 2016. The MELD score was calculated using international normalized ratio, serum billirubin and creatinine. Patients were grouped into moderate (≤15) and high (&gt; 15) MELD. Associations of the MELD score on the postprocedural morbidity, mortality and vessels patency were assessed by two-sided Fisher's exact test. ResultsSeventeen patients were identified; MELD score distribution was: ≤ 15 in 10 patients (59%) and &gt; 15 in 7 (41%). Even distribution of severe PV thrombosis was treated in both groups, performing predominately jugular access in the high MELD score group (OR 0.10; 95%; CI 0.014-0.89; p = 0.052) in contrast to a percutaneous transhepatic access in the moderate MELD score group. Analysis comparing moderate and high MELD scores was not able to demonstrate differences in mortality, morbidity or patency rates. ConclusionMELD score did not prove to be a useful method to evaluate risk of morbidity and mortality; however a high score should not contraindicate endovascular approaches. In our experience a high technical success, good patency rates and low complication rates were observed.</description><identifier>ISSN: 1665-2681</identifier><identifier>DOI: 10.5604/01.3001.0010.5287</identifier><identifier>PMID: 29055930</identifier><language>eng</language><publisher>Mexico: Elsevier</publisher><subject>Endovascular treatment ; Gastroenterology and Hepatology ; Portal hypertension ; Portal vein thrombosis</subject><ispartof>Annals of hepatology, 2017-11, Vol.16 (6), p.950-958</ispartof><rights>Fundación Clínica Médica Sur, A.C.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c417t-7e6504b9b1874656d1e028f6ab1cb3c28fe8e419da80885b8ae7efe53ebc664d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29055930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torres-Machorro, Adriana</creatorcontrib><creatorcontrib>Guerrero-Hernandez, Manuel</creatorcontrib><creatorcontrib>Anaya-Ayala, Javier E</creatorcontrib><creatorcontrib>Torre, Aldo</creatorcontrib><creatorcontrib>Laparra-Escareno, Hugo</creatorcontrib><creatorcontrib>Cuen-Ojeda, Cesar</creatorcontrib><creatorcontrib>Garcia-Alva, Ramón</creatorcontrib><creatorcontrib>Hinojosa, Carlos A</creatorcontrib><title>Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction</title><title>Annals of hepatology</title><addtitle>Ann Hepatol</addtitle><description>AbstractIntroductionEndovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective of this study is to determine if the Model for End-Stage Liver Disease (MELD) score is a useful method to evaluate the risk of morbidity and mortality during endovascular approaches. Material and methodsPatients that underwent endovascular reconstruction of the PV or spleno-mesenteric confluence were identified retrospectively. Data were collected from November 2011 to August 2016. The MELD score was calculated using international normalized ratio, serum billirubin and creatinine. Patients were grouped into moderate (≤15) and high (&gt; 15) MELD. Associations of the MELD score on the postprocedural morbidity, mortality and vessels patency were assessed by two-sided Fisher's exact test. ResultsSeventeen patients were identified; MELD score distribution was: ≤ 15 in 10 patients (59%) and &gt; 15 in 7 (41%). Even distribution of severe PV thrombosis was treated in both groups, performing predominately jugular access in the high MELD score group (OR 0.10; 95%; CI 0.014-0.89; p = 0.052) in contrast to a percutaneous transhepatic access in the moderate MELD score group. Analysis comparing moderate and high MELD scores was not able to demonstrate differences in mortality, morbidity or patency rates. ConclusionMELD score did not prove to be a useful method to evaluate risk of morbidity and mortality; however a high score should not contraindicate endovascular approaches. In our experience a high technical success, good patency rates and low complication rates were observed.</description><subject>Endovascular treatment</subject><subject>Gastroenterology and Hepatology</subject><subject>Portal hypertension</subject><subject>Portal vein thrombosis</subject><issn>1665-2681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9kc1vFCEYhzlobK3-AV7MHL1sheFzLiZNXesma2qs7cUDAeYdZWWGFZgm-9-X6dYe-MjL8_4gPAi9I_icC8w-YnJOcZ3qqJVWyRfolAjBV61Q5AS9znmHMaOctK_QSdthzjuKT9Gvi8mEQ_a5iUNT_kDzbb393Ny4mKDZjHvjSuOnx4Prubg4wsKtpz7em-zmYFLzPaZiQnMHlfsBLk65pNkVH6c36OVgQoa3T-sZuv2y_nn5dbW9vtpcXmxXjhFZVhIEx8x2lijJBBc9AdyqQRhLnKWubkEBI11vFFaKW2VAwgCcgnVCsJ6eoc0xt49mp_fJjyYddDRePxZi-q1NKt4F0AYLUNwNRjLKVAe2BSMdloN0yvZ8yfpwzNqn-G-GXPTos4MQzARxzpp0nFElCRcVJUfUpZhzguH5aoL14kRjohcnenGiFye15_1T_GxH6J87_gupwKcjAPXD7j0k7YKfvDPhLxwg7-KcqrD6Dp1bjfXNongxTGozE1TQB0CbnW4</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Torres-Machorro, Adriana</creator><creator>Guerrero-Hernandez, Manuel</creator><creator>Anaya-Ayala, Javier E</creator><creator>Torre, Aldo</creator><creator>Laparra-Escareno, Hugo</creator><creator>Cuen-Ojeda, Cesar</creator><creator>Garcia-Alva, Ramón</creator><creator>Hinojosa, Carlos A</creator><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20171101</creationdate><title>Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction</title><author>Torres-Machorro, Adriana ; Guerrero-Hernandez, Manuel ; Anaya-Ayala, Javier E ; Torre, Aldo ; Laparra-Escareno, Hugo ; Cuen-Ojeda, Cesar ; Garcia-Alva, Ramón ; Hinojosa, Carlos A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-7e6504b9b1874656d1e028f6ab1cb3c28fe8e419da80885b8ae7efe53ebc664d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Endovascular treatment</topic><topic>Gastroenterology and Hepatology</topic><topic>Portal hypertension</topic><topic>Portal vein thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torres-Machorro, Adriana</creatorcontrib><creatorcontrib>Guerrero-Hernandez, Manuel</creatorcontrib><creatorcontrib>Anaya-Ayala, Javier E</creatorcontrib><creatorcontrib>Torre, Aldo</creatorcontrib><creatorcontrib>Laparra-Escareno, Hugo</creatorcontrib><creatorcontrib>Cuen-Ojeda, Cesar</creatorcontrib><creatorcontrib>Garcia-Alva, Ramón</creatorcontrib><creatorcontrib>Hinojosa, Carlos A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Annals of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torres-Machorro, Adriana</au><au>Guerrero-Hernandez, Manuel</au><au>Anaya-Ayala, Javier E</au><au>Torre, Aldo</au><au>Laparra-Escareno, Hugo</au><au>Cuen-Ojeda, Cesar</au><au>Garcia-Alva, Ramón</au><au>Hinojosa, Carlos A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction</atitle><jtitle>Annals of hepatology</jtitle><addtitle>Ann Hepatol</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>16</volume><issue>6</issue><spage>950</spage><epage>958</epage><pages>950-958</pages><issn>1665-2681</issn><abstract>AbstractIntroductionEndovascular therapy represents a less invasive alternative to open surgery for reconstruction of the portal vein (PV) and the spleno-mesenteric venous confluence to treat Portal hypertension. The objective of this study is to determine if the Model for End-Stage Liver Disease (MELD) score is a useful method to evaluate the risk of morbidity and mortality during endovascular approaches. Material and methodsPatients that underwent endovascular reconstruction of the PV or spleno-mesenteric confluence were identified retrospectively. Data were collected from November 2011 to August 2016. The MELD score was calculated using international normalized ratio, serum billirubin and creatinine. Patients were grouped into moderate (≤15) and high (&gt; 15) MELD. Associations of the MELD score on the postprocedural morbidity, mortality and vessels patency were assessed by two-sided Fisher's exact test. ResultsSeventeen patients were identified; MELD score distribution was: ≤ 15 in 10 patients (59%) and &gt; 15 in 7 (41%). Even distribution of severe PV thrombosis was treated in both groups, performing predominately jugular access in the high MELD score group (OR 0.10; 95%; CI 0.014-0.89; p = 0.052) in contrast to a percutaneous transhepatic access in the moderate MELD score group. Analysis comparing moderate and high MELD scores was not able to demonstrate differences in mortality, morbidity or patency rates. ConclusionMELD score did not prove to be a useful method to evaluate risk of morbidity and mortality; however a high score should not contraindicate endovascular approaches. In our experience a high technical success, good patency rates and low complication rates were observed.</abstract><cop>Mexico</cop><pub>Elsevier</pub><pmid>29055930</pmid><doi>10.5604/01.3001.0010.5287</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1665-2681
ispartof Annals of hepatology, 2017-11, Vol.16 (6), p.950-958
issn 1665-2681
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a06e85cfa743489eb2ea7c07f7c8bd5d
source ScienceDirect
subjects Endovascular treatment
Gastroenterology and Hepatology
Portal hypertension
Portal vein thrombosis
title Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A19%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20the%20MELD%20Score%20Impact%20in%20the%20Outcome%20of%20Endovascular%20Portal%20Vein%20Reconstruction&rft.jtitle=Annals%20of%20hepatology&rft.au=Torres-Machorro,%20Adriana&rft.date=2017-11-01&rft.volume=16&rft.issue=6&rft.spage=950&rft.epage=958&rft.pages=950-958&rft.issn=1665-2681&rft_id=info:doi/10.5604/01.3001.0010.5287&rft_dat=%3Cproquest_doaj_%3E1954387156%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-7e6504b9b1874656d1e028f6ab1cb3c28fe8e419da80885b8ae7efe53ebc664d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1954387156&rft_id=info:pmid/29055930&rfr_iscdi=true